NASDAQ:ABMD - Abiomed Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$391.21 -4.31 (-1.09 %)
(As of 05/24/2018 11:55 AM ET)
Previous Close$395.52
Today's Range$389.61 - $403.01
52-Week Range$134.10 - $396.47
Volume12,199 shs
Average Volume643,227 shs
Market Capitalization$17.11 billion
P/E Ratio161.37
Dividend YieldN/A
Beta0.18

About Abiomed (NASDAQ:ABMD)

Abiomed logoABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400

Debt

Debt-to-Equity RatioN/A
Current Ratio5.84
Quick Ratio5.24

Price-To-Earnings

Trailing P/E Ratio161.37
Forward P/E Ratio114.06
P/E Growth4.17

Sales & Book Value

Annual Sales$593.75 million
Price / Sales29.18
Cash Flow$1.3562 per share
Price / Cash288.45
Book Value$15.57 per share
Price / Book25.13

Profitability

EPS (Most Recent Fiscal Year)$2.45
Net Income$112.17 million
Net Margins18.89%
Return on Equity17.58%
Return on Assets15.37%

Miscellaneous

Employees908
Outstanding Shares44,280,000

Abiomed (NASDAQ:ABMD) Frequently Asked Questions

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

How were Abiomed's earnings last quarter?

Abiomed (NASDAQ:ABMD) released its quarterly earnings data on Thursday, May, 3rd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.16. The medical equipment provider earned $174.44 million during the quarter, compared to analyst estimates of $164.30 million. Abiomed had a return on equity of 17.58% and a net margin of 18.89%. The business's quarterly revenue was up 39.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.33 earnings per share. View Abiomed's Earnings History.

When is Abiomed's next earnings date?

Abiomed is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Abiomed.

What price target have analysts set for ABMD?

9 brokers have issued 12 month target prices for Abiomed's stock. Their predictions range from $280.00 to $370.00. On average, they expect Abiomed's share price to reach $323.1429 in the next year. View Analyst Ratings for Abiomed.

Who are some of Abiomed's key competitors?

Who are Abiomed's key executives?

Abiomed's management team includes the folowing people:
  • Mr. Michael R. Minogue, Chairman, Chief Exec. Officer and Pres (Age 51)
  • Dr. David M. Weber Ph.D., Chief Operating Officer (Age 57)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
  • Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
  • Mr. Todd A. Trapp, CFO & VP (Age 47)

Has Abiomed been receiving favorable news coverage?

Press coverage about ABMD stock has trended somewhat positive this week, according to Accern. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Abiomed earned a coverage optimism score of 0.23 on Accern's scale. They also gave news coverage about the medical equipment provider an impact score of 45.29 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Abiomed's major shareholders?

Abiomed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include PRIMECAP MANAGEMENT COMPANY (9.23%), PRIMECAP MANAGEMENT COMPANY (9.23%), BlackRock Inc. (8.35%), Baillie Gifford & Co. (4.62%), Palo Alto Investors LP (3.04%) and Winslow Capital Management LLC (1.77%). Company insiders that own Abiomed stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for Abiomed.

Which major investors are selling Abiomed stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Millennium Management LLC, American Century Companies Inc., Wells Fargo & Company MN, Sei Investments Co., Scout Investments Inc., Blair William & Co. IL and OppenheimerFunds Inc.. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Paul Thomas and William J Bolt. View Insider Buying and Selling for Abiomed.

Which major investors are buying Abiomed stock?

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Franklin Resources Inc., BlackRock Inc., JPMorgan Chase & Co., Rockefeller Capital Management L.P., Prudential Financial Inc., Baillie Gifford & Co. and FIL Ltd. View Insider Buying and Selling for Abiomed.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $391.21.

How big of a company is Abiomed?

Abiomed has a market capitalization of $17.11 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. Abiomed employs 908 workers across the globe.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]


MarketBeat Community Rating for Abiomed (ABMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  328 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  586
MarketBeat's community ratings are surveys of what our community members think about Abiomed and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abiomed (NASDAQ:ABMD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Abiomed in the last 12 months. Their average twelve-month price target is $323.1429, suggesting that the stock has a possible downside of 17.40%. The high price target for ABMD is $370.00 and the low price target for ABMD is $280.00. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.782.752.75
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $323.1429$305.8571$301.50$180.4286
Price Target Upside: 17.40% downside9.99% upside12.61% upside6.47% downside

Abiomed (NASDAQ:ABMD) Consensus Price Target History

Price Target History for Abiomed (NASDAQ:ABMD)

Abiomed (NASDAQ:ABMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018Piper Jaffray CompaniesBoost Price TargetOverweight$360.00HighView Rating Details
5/1/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$259.00 ➝ $320.00MediumView Rating Details
4/4/2018Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$332.00MediumView Rating Details
2/16/2018SunTrust BanksReiterated RatingBuy$370.00N/AView Rating Details
2/4/2018BTIG ResearchReiterated RatingHoldHighView Rating Details
2/2/2018Leerink SwannBoost Price TargetOutperform$300.00LowView Rating Details
2/2/2018GuggenheimReiterated RatingBuy$280.00MediumView Rating Details
2/1/2018Jefferies GroupReiterated RatingBuy$300.00MediumView Rating Details
6/8/2017William BlairReiterated RatingOutperform ➝ OutperformLowView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Abiomed (NASDAQ:ABMD) Earnings History and Estimates Chart

Earnings by Quarter for Abiomed (NASDAQ:ABMD)

Abiomed (NASDAQ:ABMD) Earnings Estimates

2018 EPS Consensus Estimate: $1.86
2019 EPS Consensus Estimate: $3.21
2020 EPS Consensus Estimate: $4.48
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.40$0.43$0.41
Q2 20183$0.32$0.38$0.35
Q3 20183$0.46$0.58$0.50
Q4 20183$0.52$0.66$0.60
Q1 20193$0.58$0.73$0.67
Q2 20193$0.67$0.70$0.69
Q3 20193$0.84$0.99$0.91
Q4 20193$0.78$1.02$0.93
Q1 20202$0.99$1.28$1.14
Q2 20202$0.94$0.95$0.95
Q3 20202$1.08$1.16$1.12
Q4 20202$1.22$1.34$1.28

Abiomed (NASDAQ ABMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018$0.81N/AView Earnings Details
5/3/2018Q4 2018$0.64$0.80$164.30 million$174.44 millionViewN/AView Earnings Details
2/1/2018Q3 2018$0.50$0.70$154.00 million$154.00 millionViewN/AView Earnings Details
10/26/2017Q2 2018$0.38$0.54$131.18 million$132.80 millionViewN/AView Earnings Details
7/27/2017Q1 2018$0.42$0.45$130.83 million$132.47 millionViewN/AView Earnings Details
5/4/2017Q4 2017$0.33$0.33$122.82 million$124.68 millionViewListenView Earnings Details
1/26/2017Q317$0.29$0.34$112.71 million$114.70 millionViewListenView Earnings Details
10/27/2016Q217$0.24$0.20$103.16 million$103.00 millionViewListenView Earnings Details
7/28/2016Q117$0.23$0.29$97.23 million$103.00 millionViewListenView Earnings Details
5/3/2016Q416$0.19$0.24$90.52 million$94.00 millionViewN/AView Earnings Details
2/4/2016Q316$0.15$0.23$80.04 million$85.80 millionViewListenView Earnings Details
10/29/2015Q2$0.13$0.17$74.56 million$76.30 millionViewListenView Earnings Details
8/4/2015Q116$0.08$0.20$66.27 million$73.40 millionViewN/AView Earnings Details
5/5/2015Q415$0.12$0.28$62.55 million$67.60 millionViewN/AView Earnings Details
1/27/2015Q315$0.03$0.30$53.20 million$62.00 millionViewN/AView Earnings Details
10/30/2014Q215$0.02$0.09$48.80 million$51.80 millionViewN/AView Earnings Details
7/31/2014Q115$0.02($0.04)$297.10 million$48.80 millionViewN/AView Earnings Details
5/1/2014Q414$0.09$0.09$50.93 million$50.40 millionViewN/AView Earnings Details
1/31/2014Q314$0.05$0.11$46.00 million$46.20 millionViewN/AView Earnings Details
11/6/2013Q214$0.03$0.03$43.75 million$44.30 millionViewN/AView Earnings Details
8/1/2013Q1 2014$0.06($0.04)$42.93 million$42.70 millionViewN/AView Earnings Details
5/2/2013Q4 2013$0.08$0.09$41.87 million$43.70 millionViewN/AView Earnings Details
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 millionViewN/AView Earnings Details
11/1/2012Q213$0.05$0.20$37.47 million$37.40 millionViewN/AView Earnings Details
8/2/2012$0.10$0.16ViewN/AView Earnings Details
5/16/2012$0.07$0.07ViewN/AView Earnings Details
2/3/2012($0.01)$0.07ViewN/AView Earnings Details
11/3/2011($0.09)$0.02ViewN/AView Earnings Details
8/4/2011($0.06)($0.03)ViewN/AView Earnings Details
5/18/2011($0.04)($0.05)ViewN/AView Earnings Details
2/3/2011($0.09)($0.02)ViewN/AView Earnings Details
11/4/2010Q2 2011($0.14)($0.09)ViewN/AView Earnings Details
8/4/2010Q1 2011($0.14)($0.14)ViewN/AView Earnings Details
5/19/2010Q4 2010($0.12)($0.11)ViewN/AView Earnings Details
2/4/2010Q3 2010($0.18)($0.11)ViewN/AView Earnings Details
11/5/2009Q2 2010($0.21)($0.21)ViewN/AView Earnings Details
8/6/2009Q1 2010($0.20)($0.20)ViewN/AView Earnings Details
5/12/2009Q4 2009($0.17)($0.22)ViewN/AView Earnings Details
2/5/2009Q3 2009($0.17)($0.20)ViewN/AView Earnings Details
11/10/2008Q2 2009($0.21)($0.18)ViewN/AView Earnings Details
8/7/2008Q1 2009($0.21)($0.28)ViewN/AView Earnings Details
5/21/2008Q4 2008($0.19)($0.25)ViewN/AView Earnings Details
2/7/2008Q3 2008($0.20)($0.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Abiomed (NASDAQ:ABMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Abiomed (NASDAQ ABMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 87.79%
Insider Trading History for Abiomed (NASDAQ:ABMD)
Institutional Ownership by Quarter for Abiomed (NASDAQ:ABMD)

Abiomed (NASDAQ ABMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/8/2018Martin P SutterDirectorSell21,890$343.50$7,519,215.0046,668View SEC Filing  
5/7/2018Michael G HowleyVPSell17,500$348.11$6,091,925.0064,257View SEC Filing  
5/7/2018William J BoltSVPSell22,790$348.03$7,931,603.7066,414View SEC Filing  
2/20/2018Andrew J GreenfieldVPSell20,000$270.36$5,407,200.00View SEC Filing  
10/30/2017Dorothy E PuhyDirectorSell6,364$179.08$1,139,665.1239,532View SEC Filing  
10/30/2017Michael G HowleyVPSell10,000$178.64$1,786,400.0056,757View SEC Filing  
10/2/2017Andrew J GreenfieldVPSell11,282$169.32$1,910,268.24View SEC Filing  
8/30/2017Eric A Md RoseDirectorSell982$145.17$142,556.9413,634View SEC Filing  
8/24/2017Eric A Md RoseDirectorSell23,018$151.09$3,477,789.6224,652View SEC Filing  
8/15/2017Paul ThomasDirectorSell10,000$154.71$1,547,100.0012,172View SEC Filing  
7/31/2017David M WeberCOOSell16,500$147.63$2,435,895.00125,122View SEC Filing  
5/16/2017Michael G HowleyVPSell18,279$133.56$2,441,343.2462,105View SEC Filing  
5/8/2017David M WeberCOOSell21,250$130.89$2,781,412.50123,771View SEC Filing  
5/8/2017Dorothy E PuhyDirectorSell13,500$131.12$1,770,120.0038,249View SEC Filing  
5/8/2017Michael G HowleyVPSell600$132.84$79,704.0048,305View SEC Filing  
3/17/2017Andrew J GreenfieldVPSell10,000$124.00$1,240,000.0066,307View SEC Filing  
12/13/2016Dorothy E PuhyDirectorSell8,000$120.00$960,000.0032,749View SEC Filing  
11/30/2016Eric A Md RoseDirectorSell8,000$110.81$886,480.0021,259View SEC Filing  
9/22/2016Michael R MinogueCEOSell28,039$127.07$3,562,915.73215,488View SEC Filing  
9/21/2016Michael R MinogueCEOSell5,034$127.07$639,670.38215,782View SEC Filing  
9/19/2016Michael R MinogueCEOSell58,710$127.00$7,456,170.00215,782View SEC Filing  
8/15/2016Dorothy E PuhyDirectorSell5,160$123.94$639,530.4024,749View SEC Filing  
8/10/2016Dorothy E PuhyDirectorSell3,900$122.31$477,009.0033,811View SEC Filing  
8/8/2016Michael G HowleyVPSell17,853$119.20$2,128,077.6065,558View SEC Filing  
8/1/2016Henri A TermeerDirectorSell25,866$118.70$3,070,294.20325,778View SEC Filing  
6/29/2016Michael G HowleyVPSell10,000$106.58$1,065,800.0065,558View SEC Filing  
6/7/2016Andrew J GreenfieldVPSell9,000$104.16$937,440.0065,234View SEC Filing  
5/23/2016David M WeberCOOSell4,342$96.97$421,043.74100,159View SEC Filing  
5/16/2016David M WeberCOOSell5,604$94.56$529,914.24116,783View SEC Filing  
5/6/2016David M WeberCOOSell2,145$93.82$201,243.90117,411View SEC Filing  
5/5/2016David M WeberCOOSell52,000$95.27$4,954,040.00121,676View SEC Filing  
5/5/2016Paul ThomasDirectorSell7,500$95.14$713,550.0028,811View SEC Filing  
4/18/2016Andrew J GreenfieldVPSell10,000$99.10$991,000.0061,186View SEC Filing  
4/13/2016Michael G HowleyVPSell9,800$98.64$966,672.0062,268View SEC Filing  
4/8/2016Michael G HowleyVPSell200$98.80$19,760.0052,668View SEC Filing  
4/1/2016Dorothy E PuhyDirectorSell10,000$95.02$950,200.0047,792View SEC Filing  
3/31/2016Andrew J GreenfieldVPSell15,000$94.11$1,411,650.0058,941View SEC Filing  
3/24/2016David M WeberCOOSell5,235$89.93$470,783.55113,411View SEC Filing  
3/22/2016Andrew J GreenfieldVPSell24,800$89.06$2,208,688.0073,614View SEC Filing  
3/22/2016Dorothy E PuhyDirectorSell10,000$90.30$903,000.0052,190View SEC Filing  
3/21/2016Andrew J GreenfieldVPSell19,572$89.07$1,743,278.0473,614View SEC Filing  
3/10/2016Andrew J GreenfieldVPSell200$89.00$17,800.0054,242View SEC Filing  
3/8/2016David M WeberCOOSell17,521$85.20$1,492,789.20125,761View SEC Filing  
3/8/2016William J BoltSVPSell17,510$85.19$1,491,676.9098,392View SEC Filing  
3/7/2016David M WeberCOOSell8,111$85.21$691,138.31125,761View SEC Filing  
3/7/2016Dorothy E PuhyDirectorSell4,000$85.00$340,000.0066,190View SEC Filing  
3/7/2016William J BoltSVPSell7,987$85.20$680,492.4098,392View SEC Filing  
2/8/2016Dorothy E. PuhyDirectorSell4,000$80.47$321,880.0062,190View SEC Filing  
8/19/2015Michael R. MinogueCEOSell146,800$104.87$15,394,916.00239,718View SEC Filing  
8/17/2015Dorothy E PuhyDirectorSell2,580$103.91$268,087.80View SEC Filing  
8/14/2015Dorothy E PuhyDirectorSell2,580$105.27$271,596.60View SEC Filing  
7/17/2015Michael G HowleyVPSell21,295$70.00$1,490,650.00View SEC Filing  
6/15/2015Andrew J GreenfieldVPSell3,185$65.00$207,025.00View SEC Filing  
5/29/2015Martin P SutterDirectorBuy7,500$60.17$451,275.00View SEC Filing  
5/27/2015David M WeberCOOSell17,968$60.77$1,091,915.36View SEC Filing  
5/12/2015Michael G HowleyVPSell17,353$66.47$1,153,453.91View SEC Filing  
5/7/2015Andrew J GreenfieldVPSell3,500$71.00$248,500.00View SEC Filing  
5/7/2015Robert BowenCFOSell2,372$71.52$169,645.44View SEC Filing  
5/6/2015David M WeberCOOSell1,605$73.72$118,320.60View SEC Filing  
5/6/2015Michael R MinogueCEOSell8,840$73.12$646,380.80View SEC Filing  
5/6/2015William J BoltSVPSell1,750$74.27$129,972.50View SEC Filing  
3/23/2015David M WeberCOOSell3,765$71.08$267,616.20View SEC Filing  
10/31/2014Andrew J GreenfieldVPSell15,000$31.90$478,500.00View SEC Filing  
10/31/2014Michael R MinogueCEOSell164,000$31.14$5,106,960.00View SEC Filing  
7/28/2014Michael R MinogueCEOSell82,383$26.30$2,166,672.90View SEC Filing  
5/27/2014Andrew J GreenfieldVPSell7,026$21.10$148,248.60View SEC Filing  
5/27/2014David M WeberCOOSell10,172$21.11$214,730.92View SEC Filing  
5/27/2014Michael R MinogueCEOSell90,001$21.19$1,907,121.19View SEC Filing  
5/27/2014Robert BowenCFOSell6,820$21.11$143,970.20View SEC Filing  
5/27/2014William J BoltSVPSell8,029$21.10$169,411.90View SEC Filing  
5/15/2014David WeberCOOSell1,425$20.94$29,839.50130,482View SEC Filing  
5/15/2014Michael HowleyVPSell1,267$20.94$26,530.9874,486View SEC Filing  
5/15/2014Michael MinogueCEOSell4,433$20.94$92,827.02260,912View SEC Filing  
5/15/2014William BoltSVPSell1,110$20.94$23,243.4094,205View SEC Filing  
1/10/2014Robert BowenCFOSell37,500$30.00$1,125,000.0066,929View SEC Filing  
9/3/2013David WeberCOOSell6,500$24.00$156,000.00126,907View SEC Filing  
9/3/2013William BoltSVPSell20,000$24.00$480,000.0089,718View SEC Filing  
8/14/2013William BoltSVPSell21,534$23.35$502,818.9089,718View SEC Filing  
8/13/2013David WeberCOOSell4,400$23.00$101,200.00133,407View SEC Filing  
8/13/2013Michael HowleyVPSell8,400$23.00$193,200.0068,753View SEC Filing  
8/5/2013David WeberCOOSell7,100$22.90$162,590.00137,807View SEC Filing  
8/5/2013Michael HowleyVPSell1,600$23.03$36,848.0077,153View SEC Filing  
8/5/2013Robert BowenCFOSell2,235$22.64$50,600.4066,929View SEC Filing  
8/5/2013W Gerald AustenDirectorSell8,000$22.85$182,800.00View SEC Filing  
8/5/2013William BoltSVPSell20,166$22.70$457,768.2098,552View SEC Filing  
7/31/2013Michael R MinogueCEOSell36,500$25.04$913,960.00View SEC Filing  
7/17/2013Michael G HowleyVPSell10,000$24.45$244,500.00View SEC Filing  
7/15/2013Robert BowenCFOSell40,786$23.50$958,471.00View SEC Filing  
7/11/2013Robert BowenCFOSell1,499$23.50$35,226.50View SEC Filing  
6/4/2013David M WeberCOOSell6,519$21.20$138,202.80View SEC Filing  
6/4/2013Michael G HowleyVPSell3,881$21.20$82,277.20View SEC Filing  
6/4/2013Michael R MinogueCEOSell17,667$21.23$375,070.41View SEC Filing  
6/4/2013Robert BowenCFOSell5,298$21.20$112,317.60View SEC Filing  
6/4/2013William J BoltSVPSell4,967$21.20$105,300.40View SEC Filing  
5/29/2013Michael R MinogueCEOSell58,833$21.83$1,284,324.39View SEC Filing  
5/28/2013David M WeberCOOSell6,018$22.18$133,479.24View SEC Filing  
5/28/2013Michael G HowleyVPSell5,476$22.18$121,457.68View SEC Filing  
5/28/2013Robert BowenCFOSell5,102$22.18$113,162.36View SEC Filing  
5/28/2013William J BoltSVPSell4,629$22.18$102,671.22View SEC Filing  
5/23/2013Andrew J GreenfieldVPSell1,666$21.63$36,035.58View SEC Filing  
5/23/2013Michael R MinogueCEOSell5,666$21.62$122,498.92View SEC Filing  
5/17/2013Robert BowenCFOSell2,715$23.50$63,802.50View SEC Filing  
5/9/2013Michael R MinogueCEOSell20,000$21.00$420,000.00View SEC Filing  
5/7/2013Henri A TermeerDirectorBuy100,000$19.86$1,986,000.00View SEC Filing  
2/25/2013Henri A TermeerDirectorBuy100,000$14.98$1,498,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Abiomed (NASDAQ ABMD) News Headlines

Source:
DateHeadline
Here's Why You Should Buy Cooper Companies (COO) Stock NowHere's Why You Should Buy Cooper Companies (COO) Stock Now
finance.yahoo.com - May 23 at 4:15 PM
Allscripts Acquires HealthGrid to Improve Patient OutcomeAllscripts Acquires HealthGrid to Improve Patient Outcome
finance.yahoo.com - May 22 at 4:16 PM
Ecolab (ECL) Rolls Out HDI for Improved Food SurveillanceEcolab (ECL) Rolls Out HDI for Improved Food Surveillance
finance.yahoo.com - May 22 at 4:16 PM
Analyzing ABMD, BR, and TFX StocksAnalyzing ABMD, BR, and TFX Stocks
finance.yahoo.com - May 21 at 4:16 PM
Abiomed (ABMD) Given Average Recommendation of "Buy" by BrokeragesAbiomed (ABMD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 20 at 8:14 AM
Why ABIOMED (ABMD) Could Be an Impressive Growth StockWhy ABIOMED (ABMD) Could Be an Impressive Growth Stock
www.nasdaq.com - May 18 at 10:59 AM
Zacks: Brokerages Anticipate Abiomed (ABMD) Will Announce Quarterly Sales of $171.90 MillionZacks: Brokerages Anticipate Abiomed (ABMD) Will Announce Quarterly Sales of $171.90 Million
www.americanbankingnews.com - May 18 at 2:00 AM
Top Buys In Healthcare & IT Following Q1 EPS Exceeding Estimates And Continuing Into Q2Top Buys In Healthcare & IT Following Q1 EPS Exceeding Estimates And Continuing Into Q2
www.forbes.com - May 17 at 4:14 PM
Thermo Fisher (TMO) Gains on Latest Buyouts Despite Cost WoesThermo Fisher (TMO) Gains on Latest Buyouts Despite Cost Woes
finance.yahoo.com - May 17 at 4:14 PM
Veeva Rolls Out Nitro to Unify Healthcare Industry DataVeeva Rolls Out Nitro to Unify Healthcare Industry Data
www.zacks.com - May 17 at 9:53 AM
$0.80 EPS Expected for Abiomed (ABMD) This Quarter$0.80 EPS Expected for Abiomed (ABMD) This Quarter
www.americanbankingnews.com - May 16 at 9:16 PM
Form 4 ABIOMED INC For: May 07 Filed by: Howley Michael GForm 4 ABIOMED INC For: May 07 Filed by: Howley Michael G
www.streetinsider.com - May 10 at 4:18 PM
Here's Why You Should Invest in Intuitive Surgical Right NowHere's Why You Should Invest in Intuitive Surgical Right Now
finance.yahoo.com - May 10 at 4:18 PM
Form 4 ABIOMED INC For: May 08 Filed by: SUTTER MARTIN PForm 4 ABIOMED INC For: May 08 Filed by: SUTTER MARTIN P
www.streetinsider.com - May 10 at 9:55 AM
Form 4 ABIOMED INC For: May 07 Filed by: PUHY DOROTHY EForm 4 ABIOMED INC For: May 07 Filed by: PUHY DOROTHY E
www.streetinsider.com - May 10 at 9:55 AM
Insider Selling: Abiomed (ABMD) Director Sells 21,890 Shares of StockInsider Selling: Abiomed (ABMD) Director Sells 21,890 Shares of Stock
www.americanbankingnews.com - May 9 at 10:14 PM
Abiomed (ABMD) SVP Sells $7,931,603.70 in StockAbiomed (ABMD) SVP Sells $7,931,603.70 in Stock
www.americanbankingnews.com - May 9 at 10:14 PM
Michael G. Howley Sells 17,500 Shares of Abiomed (ABMD) StockMichael G. Howley Sells 17,500 Shares of Abiomed (ABMD) Stock
www.americanbankingnews.com - May 9 at 10:14 PM
Is ABIOMED (ABMD) Outperforming Other Medical Stocks This Year?Is ABIOMED (ABMD) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - May 9 at 4:19 PM
ABIOMED (ABMD) Earnings Beat Estimates in Q4, View ImpressiveABIOMED (ABMD) Earnings Beat Estimates in Q4, View Impressive
finance.yahoo.com - May 7 at 4:19 PM
Abiomed to Post Q2 2019 Earnings of $0.67 Per Share, William Blair Forecasts (ABMD)Abiomed to Post Q2 2019 Earnings of $0.67 Per Share, William Blair Forecasts (ABMD)
www.americanbankingnews.com - May 7 at 4:38 AM
Q1 2019 EPS Estimates for Abiomed Lifted by Leerink Swann (ABMD)Q1 2019 EPS Estimates for Abiomed Lifted by Leerink Swann (ABMD)
www.americanbankingnews.com - May 7 at 4:38 AM
Q1 2019 Earnings Estimate for Abiomed (ABMD) Issued By Piper JaffrayQ1 2019 Earnings Estimate for Abiomed (ABMD) Issued By Piper Jaffray
www.americanbankingnews.com - May 7 at 4:38 AM
Abiomed's Revenue Growth Accelerates to 40%Abiomed's Revenue Growth Accelerates to 40%
finance.yahoo.com - May 4 at 4:19 PM
Abiomeds Revenue Growth Accelerates to 40%Abiomed's Revenue Growth Accelerates to 40%
www.fool.com - May 4 at 10:46 AM
Today’s Research Reports on Stocks to Watch: Cardinal Health and ABIOMEDToday’s Research Reports on Stocks to Watch: Cardinal Health and ABIOMED
finance.yahoo.com - May 4 at 9:32 AM
Edited Transcript of ABMD earnings conference call or presentation 3-May-18 12:00pm GMTEdited Transcript of ABMD earnings conference call or presentation 3-May-18 12:00pm GMT
finance.yahoo.com - May 4 at 9:32 AM
Abiomed (ABMD) Upgraded by Zacks Investment Research to BuyAbiomed (ABMD) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - May 3 at 11:50 PM
Abiomed (ABMD) Upgraded by ValuEngine to "Strong-Buy"Abiomed (ABMD) Upgraded by ValuEngine to "Strong-Buy"
www.americanbankingnews.com - May 3 at 11:47 PM
Abiomed (ABMD) Price Target Increased to $360.00 by Analysts at Piper JaffrayAbiomed (ABMD) Price Target Increased to $360.00 by Analysts at Piper Jaffray
www.americanbankingnews.com - May 3 at 10:04 PM
Why Abiomed Stock Is Flying High TodayWhy Abiomed Stock Is Flying High Today
finance.yahoo.com - May 3 at 4:16 PM
Abiomed (ABMD) Posts  Earnings Results, Beats Expectations By $0.24 EPSAbiomed (ABMD) Posts Earnings Results, Beats Expectations By $0.24 EPS
www.americanbankingnews.com - May 3 at 3:16 PM
Abiomed Announces Q4 FY 2018 Revenue of $174 MillionAbiomed Announces Q4 FY 2018 Revenue of $174 Million
www.lse.co.uk - May 3 at 9:36 AM
Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33 ...Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33 ...
globenewswire.com - May 3 at 9:36 AM
BRIEF-Abiomed Reports Q4 GAAP Earnings Per Share $0.80BRIEF-Abiomed Reports Q4 GAAP Earnings Per Share $0.80
www.reuters.com - May 3 at 9:36 AM
Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33%, Over Prior YearAbiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33%, Over Prior Year
finance.yahoo.com - May 3 at 9:36 AM
Abiomed: Fiscal 4Q Earnings SnapshotAbiomed: Fiscal 4Q Earnings Snapshot
finance.yahoo.com - May 3 at 9:36 AM
Abiomed Earnings OutlookAbiomed Earnings Outlook
www.benzinga.com - May 2 at 4:17 PM
Abiomed (ABMD) Price Target Raised to $320.00Abiomed (ABMD) Price Target Raised to $320.00
www.americanbankingnews.com - May 1 at 2:38 PM
Research Report Identifies Altair Engineering, Safety Insurance Group, Tyler Technologies, Veracyte, Enviva Partners ...Research Report Identifies Altair Engineering, Safety Insurance Group, Tyler Technologies, Veracyte, Enviva Partners ...
globenewswire.com - May 1 at 9:40 AM
$163.84 Million in Sales Expected for Abiomed (ABMD) This Quarter$163.84 Million in Sales Expected for Abiomed (ABMD) This Quarter
www.americanbankingnews.com - May 1 at 3:50 AM
 Analysts Expect Abiomed (ABMD) Will Post Earnings of $0.64 Per Share Analysts Expect Abiomed (ABMD) Will Post Earnings of $0.64 Per Share
www.americanbankingnews.com - April 29 at 9:21 AM
Zacks Investment Research Downgrades Abiomed (ABMD) to HoldZacks Investment Research Downgrades Abiomed (ABMD) to Hold
www.americanbankingnews.com - April 25 at 12:14 PM
Abiomed (ABMD) Receives Consensus Rating of "Buy" from BrokeragesAbiomed (ABMD) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 25 at 8:50 AM
Abiomed (ABMD) Set to Announce Earnings on WednesdayAbiomed (ABMD) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 25 at 2:02 AM
Abiomed (ABMD) Given a $145.00 Price Target by Piper Jaffray AnalystsAbiomed (ABMD) Given a $145.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 19 at 11:52 PM
Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?
finance.yahoo.com - April 17 at 9:52 AM
Abiomed (ABMD) Downgraded to "Hold" at BidaskClubAbiomed (ABMD) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 16 at 12:02 PM
Abiomed (ABMD) Expected to Announce Quarterly Sales of $163.84 MillionAbiomed (ABMD) Expected to Announce Quarterly Sales of $163.84 Million
www.americanbankingnews.com - April 14 at 4:17 AM
Artificial Organs Global Market Forecast to 2023 - Market Projected to Reach $21 Billion Growing at a CAGR of 9.5%Artificial Organs Global Market Forecast to 2023 - Market Projected to Reach $21 Billion Growing at a CAGR of 9.5%
www.prnewswire.com - April 13 at 10:04 AM

SEC Filings

Abiomed (NASDAQ:ABMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Abiomed (NASDAQ:ABMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Abiomed (NASDAQ ABMD) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.